Análise da associação de alelos HLA de classe II (DRB1) com a hanseníase em uma população de São Luís/MA - Corrêa, Rita da Graça Carvalhal Frazão (2011)
<span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*135.28px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.04677);" role="presentation" dir="ltr">A hanseníase é uma doença infecto-contagiosa, que se manifesta principalmente <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*149.08px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.02068);" role="presentation" dir="ltr">por sinais e sintomas dermatoneurológicos. Estudos epidemiológicos têm mostrado <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*162.76px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.09745);" role="presentation" dir="ltr">que a variabilidade da resposta clínica à infecção causada pelo <span style="left: calc(var(--scale-factor)*462.46px); top: calc(var(--scale-factor)*162.76px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.99839);" role="presentation" dir="ltr">M.leprae <span style="left: calc(var(--scale-factor)*516.10px); top: calc(var(--scale-factor)*162.76px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00121);" role="presentation" dir="ltr">está <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*176.56px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00056);" role="presentation" dir="ltr">associadas <span style="left: calc(var(--scale-factor)*155.50px); top: calc(var(--scale-factor)*176.56px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00317);" role="presentation" dir="ltr">aos <span style="left: calc(var(--scale-factor)*185.18px); top: calc(var(--scale-factor)*176.56px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.999749);" role="presentation" dir="ltr">fatores <span style="left: calc(var(--scale-factor)*232.18px); top: calc(var(--scale-factor)*176.56px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00089);" role="presentation" dir="ltr">genéticos <span style="left: calc(var(--scale-factor)*293.92px); top: calc(var(--scale-factor)*176.56px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00185);" role="presentation" dir="ltr">do <span style="left: calc(var(--scale-factor)*317.65px); top: calc(var(--scale-factor)*176.56px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.999057);" role="presentation" dir="ltr">hospedeiro. O <span style="left: calc(var(--scale-factor)*410.58px); top: calc(var(--scale-factor)*176.56px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.999872);" role="presentation" dir="ltr">sistema <span style="left: calc(var(--scale-factor)*462.34px); top: calc(var(--scale-factor)*176.56px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.999675);" role="presentation" dir="ltr">HLA (<span style="left: calc(var(--scale-factor)*500.02px); top: calc(var(--scale-factor)*176.56px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.999955);" role="presentation" dir="ltr">Human <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*190.36px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.0214);" role="presentation" dir="ltr">Leucocitary Antigen <span style="left: calc(var(--scale-factor)*210.77px); top: calc(var(--scale-factor)*190.36px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.04294);" role="presentation" dir="ltr">Antígeno Leucocitário Humano) região de genes altamente <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*204.28px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.01794);" role="presentation" dir="ltr">polimórficos localizados no braço curto do cromossomo 6 (6p21) tem sido apontado <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*218.08px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00568);" role="presentation" dir="ltr">como relevante, principalmente na associação HLA-DRB1 e hanseníase. O presente <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*231.76px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.04539);" role="presentation" dir="ltr">estudo investigou a frequência de alelos HLA de <span style="left: calc(var(--scale-factor)*359.59px); top: calc(var(--scale-factor)*231.76px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.03698);" role="presentation" dir="ltr">classe II <span style="left: calc(var(--scale-factor)*410.35px); top: calc(var(--scale-factor)*231.76px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.04052);" role="presentation" dir="ltr">(DRB1) e a associação <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*245.56px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.0526);" role="presentation" dir="ltr">com a hanseníase em uma população de São Luís - MA. Para a análise do <span style="left: calc(var(--scale-factor)*510.82px); top: calc(var(--scale-factor)*245.56px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.997464);" role="presentation" dir="ltr">lócus <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*259.48px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.09323);" role="presentation" dir="ltr">HLA-DRB1, foi realizado um estudo do tipo caso-controle, com oitenta e cinco <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*273.31px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.03456);" role="presentation" dir="ltr">indivíduos com hanseníase e oitenta e cinco  indivíduos sadios no período de maio <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*287.11px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.04068);" role="presentation" dir="ltr">de 2008 a setembro de 2010. Os dados referentes aos aspectos epidemiológicos, <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*300.91px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.02253);" role="presentation" dir="ltr">clínicos e operacionais dos casos de hanseníase foram coletados, utilizando-se um <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*314.71px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.0051);" role="presentation" dir="ltr">formulário com perguntas abertas e fechadas. Os dados genéticos foram obtidos por <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*328.51px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.0513);" role="presentation" dir="ltr">meio da coleta de sangue para a extração do DNA genômico, sendo a tipificação <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*342.19px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.06363);" role="presentation" dir="ltr">HLA realizada pelo método SSOP (<span style="left: calc(var(--scale-factor)*286.13px); top: calc(var(--scale-factor)*342.19px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.03174);" role="presentation" dir="ltr">Sequence Specific Oligonucleotides Probes <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*356.11px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00759);" role="presentation" dir="ltr">Sondas de Oligonucleotídeos Sequência Específica). A ocorrência da associação foi <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*369.91px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.01408);" role="presentation" dir="ltr">avaliada pela comparação das frequências dos alelos em ambos os grupos sendo o <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*383.59px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.03065);" role="presentation" dir="ltr">resultado considerado significante quando p < 0,05. Foi calculado <span style="left: calc(var(--scale-factor)*449.98px); top: calc(var(--scale-factor)*383.59px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.0247);" role="presentation" dir="ltr">Odds Ratio <span style="left: calc(var(--scale-factor)*516.22px); top: calc(var(--scale-factor)*383.59px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.996243);" role="presentation" dir="ltr">com <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*397.51px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.0326);" role="presentation" dir="ltr">intervalo de confiança de 95%. Os resultados mostraram que 51,8% eram do sexo <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*411.31px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00447);" role="presentation" dir="ltr">masculino e 62,4% da cor parda. A faixa etária de 40 a 64 anos foi a mais acometida <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*425.11px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.01025);" role="presentation" dir="ltr">pela hanseníase (41,2%) sendo a forma clínica virchowiana (42,5%) mais frequente. <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*438.91px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.07443);" role="presentation" dir="ltr">A classificação operacional multibacilar foi predominante (72,9%). O alelo HLA- <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*452.71px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00074);" role="presentation" dir="ltr">DRB1*16 <span style="left: calc(var(--scale-factor)*143.74px); top: calc(var(--scale-factor)*452.71px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.999036);" role="presentation" dir="ltr">apresentou <span style="left: calc(var(--scale-factor)*212.18px); top: calc(var(--scale-factor)*452.71px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00269);" role="presentation" dir="ltr">frequência <span style="left: calc(var(--scale-factor)*276.80px); top: calc(var(--scale-factor)*452.71px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.0034);" role="presentation" dir="ltr">maior <span style="left: calc(var(--scale-factor)*315.41px); top: calc(var(--scale-factor)*452.71px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.993761);" role="presentation" dir="ltr">no <span style="left: calc(var(--scale-factor)*337.34px); top: calc(var(--scale-factor)*452.71px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.998577);" role="presentation" dir="ltr">grupo <span style="left: calc(var(--scale-factor)*376.56px); top: calc(var(--scale-factor)*452.71px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.996772);" role="presentation" dir="ltr">com <span style="left: calc(var(--scale-factor)*408.07px); top: calc(var(--scale-factor)*452.71px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.998378);" role="presentation" dir="ltr">hanseníase, <span style="left: calc(var(--scale-factor)*482.02px); top: calc(var(--scale-factor)*452.71px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.999456);" role="presentation" dir="ltr">mostrando <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*466.41px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.04065);" role="presentation" dir="ltr">tendência associada à suscetibilidade (9.41% <span style="left: calc(var(--scale-factor)*343.87px); top: calc(var(--scale-factor)*466.41px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00023);" role="presentation" dir="ltr">vs. <span style="left: calc(var(--scale-factor)*364.99px); top: calc(var(--scale-factor)*466.41px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.999902);" role="presentation" dir="ltr">4.12%, <span style="left: calc(var(--scale-factor)*408.19px); top: calc(var(--scale-factor)*466.41px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00146);" role="presentation" dir="ltr">OR<span style="left: calc(var(--scale-factor)*426.19px); top: calc(var(--scale-factor)*466.41px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.02221);" role="presentation" dir="ltr">=2.41, IC=0.96-6.08, <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*480.33px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.08724);" role="presentation" dir="ltr">p=0.05). O alelo HLA-DRB1*11 foi menos frequente no grupo com hanseníase <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*494.01px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00245);" role="presentation" dir="ltr">(6.47% <span style="left: calc(var(--scale-factor)*128.18px); top: calc(var(--scale-factor)*494.01px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00013);" role="presentation" dir="ltr">vs <span style="left: calc(var(--scale-factor)*144.98px); top: calc(var(--scale-factor)*494.01px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.01878);" role="presentation" dir="ltr">11.76%, <span style="left: calc(var(--scale-factor)*193.97px); top: calc(var(--scale-factor)*494.01px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.994793);" role="presentation" dir="ltr">OR<span style="left: calc(var(--scale-factor)*211.85px); top: calc(var(--scale-factor)*494.01px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.02065);" role="presentation" dir="ltr">=0.51 IC=0.23<span style="left: calc(var(--scale-factor)*296.21px); top: calc(var(--scale-factor)*494.01px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.04031);" role="presentation" dir="ltr">1.12, p=0.09). A frequência dos alelos HLA-<span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*507.93px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.06572);" role="presentation" dir="ltr">DRB1 entre o grupo controle e subgrupos mostraram que o alelo HLA-DRB1*16 <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*521.61px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00035);" role="presentation" dir="ltr">(16.13% <span style="left: calc(var(--scale-factor)*135.98px); top: calc(var(--scale-factor)*521.61px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00023);" role="presentation" dir="ltr">vs. <span style="left: calc(var(--scale-factor)*157.46px); top: calc(var(--scale-factor)*521.61px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.997333);" role="presentation" dir="ltr">8.24%, <span style="left: calc(var(--scale-factor)*200.81px); top: calc(var(--scale-factor)*521.61px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00146);" role="presentation" dir="ltr">OR<span style="left: calc(var(--scale-factor)*218.81px); top: calc(var(--scale-factor)*521.61px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.06412);" role="presentation" dir="ltr">=4.10, IC =1.27-13.27, p=0,010) e o alelo HLA-DRB1*14 <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*535.41px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00035);" role="presentation" dir="ltr">(5.% <span style="left: calc(var(--scale-factor)*115.94px); top: calc(var(--scale-factor)*535.41px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00023);" role="presentation" dir="ltr">vs. <span style="left: calc(var(--scale-factor)*137.42px); top: calc(var(--scale-factor)*535.41px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00311);" role="presentation" dir="ltr">3.53%, <span style="left: calc(var(--scale-factor)*181.10px); top: calc(var(--scale-factor)*535.41px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00146);" role="presentation" dir="ltr">OR<span style="left: calc(var(--scale-factor)*199.13px); top: calc(var(--scale-factor)*535.41px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.0611);" role="presentation" dir="ltr">=4.63, IC =1.00-21.08, p=0,032) foram mais frequentes com <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*549.33px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00121);" role="presentation" dir="ltr">significância <span style="left: calc(var(--scale-factor)*162.82px); top: calc(var(--scale-factor)*549.33px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.995856);" role="presentation" dir="ltr">estatística <span style="left: calc(var(--scale-factor)*228.89px); top: calc(var(--scale-factor)*549.33px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00036);" role="presentation" dir="ltr">associadas <span style="left: calc(var(--scale-factor)*301.19px); top: calc(var(--scale-factor)*549.33px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00245);" role="presentation" dir="ltr">às <span style="left: calc(var(--scale-factor)*326.00px); top: calc(var(--scale-factor)*549.33px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00355);" role="presentation" dir="ltr">formas <span style="left: calc(var(--scale-factor)*374.92px); top: calc(var(--scale-factor)*549.33px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00185);" role="presentation" dir="ltr">da <span style="left: calc(var(--scale-factor)*400.56px); top: calc(var(--scale-factor)*549.33px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.998279);" role="presentation" dir="ltr">doença. <span style="left: calc(var(--scale-factor)*455.74px); top: calc(var(--scale-factor)*549.33px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00023);" role="presentation" dir="ltr">Os <span style="left: calc(var(--scale-factor)*483.33px); top: calc(var(--scale-factor)*549.33px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00045);" role="presentation" dir="ltr">resultados <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*563.13px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00784);" role="presentation" dir="ltr">demonstraram a suscetibilidade genética associada às formas clínicas. O alelo HLA- <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*576.93px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.01961);" role="presentation" dir="ltr">DRB1*16 foi associado à forma virchowiana (LL), enquanto o alelo HLA-DRB1*14 à <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*590.73px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00304);" role="presentation" dir="ltr">forma <span style="left: calc(var(--scale-factor)*124.66px); top: calc(var(--scale-factor)*590.73px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.998526);" role="presentation" dir="ltr">tuberculóide <span style="left: calc(var(--scale-factor)*198.74px); top: calc(var(--scale-factor)*590.73px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00254);" role="presentation" dir="ltr">(TT). A <span style="left: calc(var(--scale-factor)*250.49px); top: calc(var(--scale-factor)*590.73px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.996882);" role="presentation" dir="ltr">baixa <span style="left: calc(var(--scale-factor)*287.88px); top: calc(var(--scale-factor)*590.73px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00261);" role="presentation" dir="ltr">frequência <span style="left: calc(var(--scale-factor)*352.86px); top: calc(var(--scale-factor)*590.73px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00185);" role="presentation" dir="ltr">do <span style="left: calc(var(--scale-factor)*375.07px); top: calc(var(--scale-factor)*590.73px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.01083);" role="presentation" dir="ltr">HLA-DRB1*11 <span style="left: calc(var(--scale-factor)*461.26px); top: calc(var(--scale-factor)*590.73px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.999485);" role="presentation" dir="ltr">sugere <span style="left: calc(var(--scale-factor)*506.70px); top: calc(var(--scale-factor)*590.73px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.999143);" role="presentation" dir="ltr">novas <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*604.53px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.999135);" role="presentation" dir="ltr">investigações relacionadas ao seu possível efeito de proteção para a doença. <span style="left: calc(var(--scale-factor)*85.10px); top: calc(var(--scale-factor)*645.96px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.999246);" role="presentation" dir="ltr">Palavras-chave: <span style="left: calc(var(--scale-factor)*188.81px); top: calc(var(--scale-factor)*645.96px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00117);" role="presentation" dir="ltr">Hanseníase. <span style="left: calc(var(--scale-factor)*271.37px); top: calc(var(--scale-factor)*645.96px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.995021);" role="presentation" dir="ltr">Gene <span style="left: calc(var(--scale-factor)*315.61px); top: calc(var(--scale-factor)*645.96px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00168);" role="presentation" dir="ltr">HLA-DRB1. <span style="left: calc(var(--scale-factor)*393.43px); top: calc(var(--scale-factor)*645.96px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.999581);" role="presentation" dir="ltr">Estudo <span style="left: calc(var(--scale-factor)*445.69px); top: calc(var(--scale-factor)*645.96px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(1.00185);" role="presentation" dir="ltr">de A<span style="left: calc(var(--scale-factor)*482.26px); top: calc(var(--scale-factor)*645.96px); font-size: calc(var(--scale-factor)*12.00px); font-family: sans-serif; transform: scaleX(0.998935);" role="presentation" dir="ltr">ssociação.